Nifekalant hydrochloride suppresses severe electrical storm in patients with malignant ventricular tachyarrhythmias

Circulation Journal

Volumn 69, Issue 12, 2005, Pages 1508-1513

  Washizuka, Takashi ^a   Chinushi, Masaomi ^a   Watanabe, Hiroshi ^a   Hosaka, Yukio ^a   Komura, Satoru ^a   Sugiura, Hirotaka ^a   Hirono, Takashi ^a   Furushima, Hiroshi ^a   Tanabe, Yasutaka ^a   Aizawa, Yoshifusa ^a  

^a NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

Author keywords

Implantable cardioverter defibrillator; Nifekalant hydrochloride; Severe electrical storm

Indexed keywords

NIFEKALANT; SODIUM CHANNEL;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFIBRILLATOR; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE TACHYCARDIA; HUMAN; MAJOR CLINICAL STUDY; MALE; SEDATION;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; PYRIMIDINONES; SALVAGE THERAPY; TACHYCARDIA, VENTRICULAR;

EID: 28544444236     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.69.1508     Document Type: Article

References (29)

1. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia: Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996; 335: 1933 - 1940.
2. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997; 337: 1576 - 1583.
3. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877- 883.
4. Credner SC, Klingenheben T, Mauss O, Sticherling C, Hohnloser SH. Electrical storm in patients with transvenous implantable cardioverter- defibrillators: Incidence, management and prognostic implications. J Am Coll Cardiol 1998; 32: 1909 - 1915.
5. Greene M, Newman D, Geist M, Paquette M, Heng D, Dorian P. Is electrical storm in ICD patients the sign of a dying heart? Outcome of patients with clusters of ventricular tachyarrhythmias. Europace 2000; 2: 263 - 269.
6. Exner DV, Pinski SL, Wyse DG, Renfroe EG, Follmann D, Gold M, et al. Electrical storm presages nonsudden death: The antiarrhythmics versus implantable defibrillators (AVID) trial. Circulation 2001; 103: 2066 - 2071.
7. Hurst TM, Hinrichs M, Breidenbach C, Katz N, Waldecker B. Detection of myocardial injury during transvenous implantation of automatic cardioverter-defibrillators. J Am Coll Cardiol 1999; 34: 402 - 408.
8. 2+ overload causes failed electrical defibrillation and post-shock reinitiation of fibrillation. J Mol Cell Cardiol 1998; 30: 2183 -2192.
9. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999; 79: 215 - 262.
10. Bansch D, Bocker D, Brunn J, Weber M, Breithardt G, Block M. Clusters of ventricular tachycardias signify impaired survival in patients with idiopathic dilated cardiomyopathy and implantable cardioverter defibrillators. J Am Coll Cardiol 2000; 36: 566 - 573.
11. Katakami T, Yokoyama T, Miyamoto M, Mori H, Kawauchi N, Nobori T, et al. Synthesis and pharmacological studies of N-substituted 6-[(2-aminoethyl)amino]- 1,3-dimethyl-2,4(1H,3H)-pyrimidinediones, novel class III antiarrhythmic agents. J Med Chem 1992; 35: 3325 - 3330.
12. Nakaya H, Tohse N, Takeda Y, Kanno M. Effects of MS-551, a new class III antiarrhythmic drug, on action potential and membrane currents in rabbit ventricular myocytes. Br J Pharmacol 1993; 109: 157 - 163.
13. Martin DK, Nakaya Y, Wyse KR, Bursill JA, West PD, Campbell TJ. Inhibition of ATP-sensitive potassium channels in cardiac myocytes by the novel class III antiarrhythmic agent MS-551. Pharmacol Toxicol 1995; 77: 65 - 70.
14. Sato R, Koumi S, Hisatome I, Takai H, Aida Y, Oyaizu M, et al. A new class III antiarrhythmic drug, MS-551, blocks the inward rectifier potassium channel in isolated guinea pig ventricular myocytes. J Pharmacol Exp Ther 1995; 274: 469 - 474.
15. Kamiya J, Ishii M, Katakami T. Antiarrhythmic effects of MS-551, a new class III antiarrhythmic agent, on canine models of ventricular arrhythmia. Jpn J Pharmacol 1992; 58: 107 - 115.
16. Kondoh K, Hashimoto H, Nishiyama H, Umemura K, Ozaki T, Uematsu T, et al. Effects of MS-551, a new class III antiarrhythmic drug, on programmed stimulation-induced ventricular arrhythmias, electrophysiology, and hemodynamics in a canine myocardial infarction model. J Cardiovasc Pharmacol 1994; 23: 674 - 680.
17. Friedrichs GS, Chi L, Gralinski MR, Black SC, Basler GC, Mu DX, et al. MS-551 protects against ventricular fibrillation in a chronic canine model of sudden cardiac death. J Cardiovasc Pharmacol 1995; 25: 314 - 323.
18. Hashimoto K, Haruno A, Hirasawa A, Awaji T, Xue Y, Wu Z. Effects of the new class III antiarrhythmic drug MS-551 and d-sotalol on canine coronary ligation-reperfusion ventricular arrhythmias. Jpn J Pharmacol 1995; 68: 1-9.
19. Koizumi T, Komiyama N, Komuro I, Tanigawa T, Iwase T, Ishiwata S, et al. Efficacy of nifekalant hydrochloride on the treatment of life-threatening ventricular tachyarrhythmias during reperfusion for acute myocardial infarction. Cardiovasc Drugs Ther 2001; 15: 363 - 365.
20. Takenaka K, Yasuda S, Miyazaki S, Kurita T, Sutani Y, Morii I, et al. Initial experience with nifekalant hydrochloride (MS-551), a novel class III antiarrhythmic agent, in patients with acute extensive infarction and severe ventricular dysfunction. Jpn Circ J 2001; 65: 60 - 62.
21. Igawa M, Aonuma K, Okamoto Y, Hiroe M, Hiraoka M, Isobe M. Anti-arrhythmic efficacy of nifekalant hydrochloride, a pure class III anti-arrhythmic agent, in patients with healed myocardial infarction and inducible sustained ventricular tachycardia. J Cardiovasc Pharmacol 2002; 40: 735 - 742.
22. Sahara M, Sagara K, Yamashita T, Iinuma H, Satomi K, Fu LH, et al. Nifekalant hydrochroride, a novel class III antiarrhythmic agent, suppressed postoperative recurrent ventricular tachycardia in patient undergoing coronary artery bypass grafting and the Dor approach. Circ J 2003; 67: 712 - 714.
23. Miyoshi M, Yasuda S, Miyazaki S, Ueno K, Morii I, Satomi K, et al. Intravenous administration of nifekalant hydrochloride for the prevention of ischemia-induced ventricular tachyarrhythmia in patients with renal failure undergoing hemodialysis. Circ J 2003; 67: 898 - 900.
24. Epstein AE, Kay GN, Plumb VJ, Dailey SM, Anderson PG. Gross and microscopic pathological changes associated with nonthoracotomy implantable defibrillator leads. Circulation 1998; 98: 1517-1524.
25. Izawa A, Kinishita O, Shiba Y, Takahashi W, Uchikawa S, Imamura H, et al. Pervutaneous cardiopulmonary support aids resuscitation from sustained ventricular tachycardia. Circ J 2003; 67: 1061 - 1063.
26. Levine JH, Massumi A, Scheinman MM, Winkle RA, Platia EV, Chilson DA, et al. Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias: Intravenous Amiodarone Multicenter Trial Group. J Am Coll Cardiol 1996; 27: 67 - 75.
27. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction: The SWORD Investigators (Survival With Oral d-Sotalol). Lancet 1996; 348: 7-12.
28. Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias: Electrophysiologic Study Versus Electrocardiographic Monitoring investigators. N Engl J Med 1993; 329: 452 - 458.
29. Murakawa Y, Yamashita T, Kanese Y, Omata M. Can a class III antiarrhythmic drug improve electrical defibrillation efficacy during ventricular fibrillation? J Am Coll Cardiol 1997; 29: 688 - 692.